RJA
BLRX

Raymond James & Associates’s BioLineRX BLRX Stock Holding History

Raymond James & Associates’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-315
Closed -$35K – 4100
2021
Q1 		$35K Buy
+315
New +$37.9K ﹤0.01% 3878

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Raymond James & Associates's BLRX Position: Q2 2021 in Review

Raymond James & Associates sold out of BioLineRX (BLRX) in Q2 2021, closing a stake of 315 shares — an estimated $35K sold.

Raymond James & Associates first reported a position in BLRX in Q1 2021 and held it in 1 quarter. The position peaked at $35K in Q1 2021. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2021.

  • Raymond James & Associates reported no remaining BioLineRX position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 315 BioLineRX shares in Q2 2021, an estimated $35K.
  • Raymond James & Associates first reported a position in BioLineRX in Q1 2021 and held it in 1 quarter.
  • Raymond James & Associates's BioLineRX position peaked at $35K in Q1 2021.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.